|
In June 2004, David Smoller, Ph.D., joined Sigma-Aldrich as the Vice President of R&D. In this role, he is helping to expand Sigma-Aldrich’s leadership position through the development of new and innovative products for Life Science and High Technology research. Dr. Smoller, is involved in the implementation of a number of commercial initiatives in the areas Cell Culture, Proteomics, Genomics, Cell Biology and Organic Chemistry. In October of 2005, he expanded his role from R and D to operations, heading up both R and D and operations for the Research Biotech Business Unit. He was also promoted at this time to the Key Management Group for Sigma-Aldrich Corporation. In July 2007, Dr. Smoller was promoted to his current position of President of the Research Biotech Business Unit and now is part of the Executive Management Group for Sigma-Aldrich. Most recently he was CEO and President of ProteoPlex, a seed stage spinout focusing on functional genomics. Dr. Smoller founded Proteoplex in 2001 and led the St. Louis-based company through its product development and final acquisition. In 1992, Dr. Smoller founded Genome Systems, Inc., in St. Louis, which provided the scientific community with access to genome project-related technologies. Dr. Smoller stayed at the helm of the organization during its acquisition in 1996 by the Incyte Corporation, based in Palo Alto, California. Dr. Smoller was promoted to Senior Vice President and leader of the St. Louis organization, growing the staff to more than 250 people. During his tenure at Incyte, his responsibilities expanded and included the management of $150 Million Genomic Business Unit. This responsibility included overseeing the management of 700 hundred employees, as well as managing the strategic planning, product marketing, and research and development strategy of the unit. . Dr. Smoller earned a doctorate degree in Molecular Biology and a bachelor’s degree in Biology from Emory University in Atlanta, Georgia. He completed a postdoctoral fellowship at Washington University in the Drosophila Genome project and a postdoctoral fellowship at Monsanto Corporation. Dr. Smoller, is a Board member of Center of Emerging Technologies, St. Louis Academy of Science and Vice President of the St. Louis, Academy of Science.
|
Contact Us